Global Autoimmune Hepatitis Market – Industry Trends and Forecast to 2029

Global Autoimmune Hepatitis Market, By Type (Type 1, Type 2), Treatment (Medications, Liver Transplant, Others), Diagnosis (Liver Biopsy, Blood Tests, Imaging Tests, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029

Market Analysis and Size

In recent years, the autoimmune hepatitis market is anticipated to grow rapidly during the forecast period. According to the 2019 study "Burden of Liver Diseases in the World," liver illness causes roughly 2 million fatalities worldwide, with 1 million deaths due to cirrhosis complications and 1 million deaths due to viral hepatitis and hepatocellular cancer. Cirrhosis is the 11th most prevalent cause of mortality globally, while liver cancer is the 16th most common cause of death. They are responsible for 3.5 percent of all deaths worldwide.

Data Bridge Market Research analyses that the autoimmune hepatitis market was valued at USD 156.76 million in 2021 and is expected to reach USD 210.61 million by 2029, registering a CAGR of 3.70% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Autoimmune hepatitis is a rare but deadly liver condition. The body assaults itself when it misidentifies healthy tissue and cells as infected tissue and cells, and antibodies are produced to attack the healthy liver cells. Autoimmune hepatitis can strike suddenly or progress gradually. The aetiology of the condition is unknown, but it may be linked to other systemic diseases or pharmaceutical exposure in some cases.

Report Scope and Market Segmentation

Autoimmune Hepatitis Market Dynamics

Drivers

• Rise in the prevalence of autoimmune hepatitis

The rising prevalence of autoimmune hepatitis is a major factor driving the autoimmune hepatitis market's growth rate. Enlarged veins in the oesophagus, fluid accumulation in the abdomen, liver failure, and liver cancer are some of the problems linked with such diseases. 

• Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of autoimmune hepatitis market is the rising healthcare expenditure which helps in improving its infrastructure.

Furthermore, rising initiatives by public and private organizations to spread awareness about the will expand the autoimmune hepatitis market. Additionally, high disposable income and changing lifestyle of people will result in the expansion of autoimmune hepatitis market. Along with this, rising geriatric population and surge in medical tourism will enhance the market's growth rate.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the autoimmune hepatitis market growth. Along with this, surging drug approvals and launches will increase the market’s growth rate.

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the autoimmune hepatitis market growth during the forecast period.

Restraints/Challenges

On the other hand, the high cost of the treatment will obstruct the market's growth rate. The lack of healthcare infrastructure in developing economies and low awareness about autoimmune hepatitis will pose major challenges to the market’s growth rate. Additionally, the dearth of skilled professionals and miss diagnosis will restrain and further impede the growth rate of the market during the forecast period of 2022-2029.

This autoimmune hepatitis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the autoimmune hepatitis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Autoimmune hepatitis is an uncommon disease that affects four times as many women as it does men. Type 1 is the most common and is detected more frequently in adults. Type 2 diabetes is more frequent in youngsters and has a more severe disease course. New cases are expected to be 1-2 per 100,000 each year, with overall cases being around 24 per 100,000.

Autoimmune hepatitis market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Autoimmune Hepatitis Market

Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. Due to the financial crisis and the delay in specialty healthcare delivery while prioritizing COVID-19-related treatments, healthcare systems around the world have been severely disrupted in the aftermath of the coronavirus pandemic. Patients were unable to see their controls for a variety of reasons, including difficulty accessing a doctor, fear of infection transmission, inability to continue therapies and essential procedures due to pandemic restrictions. Such considerations may have a negative impact on the market of autoimmune hepatitis in recent months.

Global Autoimmune Hepatitis Market Scope

The autoimmune hepatitis market is segmented on the basis of type, treatment, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Type 1
• Type 2

Treatment

• Medications
  • Corticosteroids
  • Immune system suppressors
• Liver Transplant
• Others

Diagnosis

• Liver Biopsy
• Blood Tests
• Imaging Tests
  • Ultrasound
  • MRI
  • CT scan
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Autoimmune Hepatitis Market Regional Analysis/Insights

The autoimmune hepatitis market is analysed and market size insights and trends are provided by country, type, treatment, diagnosis, route of administration, end-users and distribution channel as referenced above.

The countries covered in the autoimmune hepatitis market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the autoimmune hepatitis market because of the growing presence of major key players and the rising number of research and development activities will further propel the market’s growth rate in this region. Additionally, increase in number of FDA approval drugs will further propel the market’s growth rate in this region. 

Asia-Pacific are expected to grow during the forecast period due to surging number of generic manufacturers and growing government initiatives in this region. Also, development of healthcare infrastructure will further propel the market’s growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Autoimmune Hepatitis Market Share Analysis

The autoimmune hepatitis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to autoimmune hepatitis market.

Some of the major players operating in the autoimmune hepatitis market are:

• Pfizer Inc. (US)
• GlaxoSmithKline plc (UK)
• Novartis AG (Switzerland)
• Mylan N.V. (US)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Sanofi (France)
• Boehringer Ingelheim International GmbH. (Germany)
• AstraZeneca (UK)
• Johnson & Johnson Private Limited (US)
• Bayer AG (Germany)
• Merck & Co., Inc. (US)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Bristol-Myers Squibb Company (US)
• Cadila Pharmaceuticals (India) 
• Eli Lilly and Company (US)
• LEO Pharma A/S (Denmark)
• Cipla Inc. (US)
• Aurobindo Pharma (India)
• Lupin (India)
• Sumitomo Corporation (Japan)